KLRA
Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. (KLRA) has 7 SEC Form 4 filings (15 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Jun 11, 2026.
Insiders have net bought $326.8M over the trailing 6 months. The largest single insider purchase in this window was $134.4M by Director, 10% Owner Kaplan Andrew T. on Apr 20, 2026.
- Industry:Biotechnology
- CEO:Ronald C. Renaud Jr.
- Employees:145
- HQ:Waltham, MA, US
- IPO:2026-04-17
Insider Buying
$326.8M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$2.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
RTW INVESTMENTS, LPFirst filing | 10% Owner | Purchase | 500,000 | $8.0M | Apr 22 | SEC ↗ |
Koppel AdamFirst filing | Director, 10% Owner | Purchase | 1,562,500 | $25.0M | Apr 20 | SEC ↗ |
Kaplan Andrew T.First filing | Director, 10% Owner | Purchase | 8,398,438 | $134.4M | Apr 20 | SEC ↗ |
| 10% Owner | Purchase | 1,562,500 | $25.0M | Apr 20 | SEC ↗ | |
| 10% Owner | Purchase | 8,398,438 | $134.4M | Apr 20 | SEC ↗ |
Related companies
Kailera Therapeutics, Inc. is in the Healthcare sector.